Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-Iodobenzovesamicol (IBVM) is a radiolabeled cholinergic neuron marker used primarily in research and clinical imaging. It acts as a high-affinity ligand for the vesicular acetylcholine transporter (VAChT), allowing visualization of cholinergic nerve terminals in the brain using single-photon emission computed tomography (SPECT) or positron emission tomography (PET). Radiolabeled forms such as [^123I]IBVM and [^125I]IBVM are utilized for animal studies and human brain imaging to assess cholinergic function, particularly in neurodegenerative diseases like Alzheimer's disease. The compound is highly specific for VAChT and does not significantly bind to other neurotransmitter systems. Its mechanism enables non-invasive mapping of cholinergic deficits associated with cognitive disorders[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-iodobenzovesamicol.